Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | LSS | P48449 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159161 | 0.82 | KCNH2 (0.38) | LSSMAPK11MAPK14AKT1MAPK13 | |
| SCHEMBL6162408 | 0.80 | HTR6 (0.38) | LSSCYP2D6HRH3MAPK11MAPK14 | |
| SCHEMBL6160893 | 0.76 | HTR6 (0.37) | LSSMAPK11MAPK14AKT1MAPK13 | |
| SCHEMBL6163249 | 0.72 | GCGR (0.40) | LSSMAPK11MAPK14AKT1MAPK13 | |
| SCHEMBL5219347 | 0.71 | MAPK11 (0.39) | TLR9TLR8TLR7MCHR1MAPK11 | |
| SCHEMBL6164467 | 0.66 | RIPK3 (0.40) | LSSMAPK11MAPK14 | |
| SCHEMBL1921902 | 0.65 | BTK (0.46) | NR3C1 | |
| SCHEMBL6158928 | 0.64 | ALKBH3 (0.37) | MAPK11MAPK14AKT1MAPK13MAPK12 | |
| SCHEMBL5454948 | 0.62 | MAPK11 (0.53) | TLR8TLR7MAPK11MAPK14MAPK13 | |
| SCHEMBL12120376 | 0.60 | FPR2 (0.48) | CYP2D6HRH3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542680-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1219701-B1 | Transparent bar soap composition | SHISEIDO HONECAKE INDUSTRY CO (JP) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004022055-A1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES S TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| US-6656893-B2 | Sodium salt or a mixed sodium/potassium salt of a fatty acid, amphoteric surfactant; a nonionic surfactant, and at least one glycerin derivative. | SHISEIDO HONECAKE INDUSTRY CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20020132743-A1 | Transparent bar soap composition | P&PF CO., LTD. (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1219701-A1 | Transparent bar soap composition | Shiseido Honecake Industry Co., Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132743-A1 | Transparent bar soap composition | SGMS1, PHOSPHO1, SGMS2 | NR3C1 2959/4885TLR9 1658/4885TLR8 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.